Novavax WKN: A2PKMZ ISIN: US6700024010 Forum: Aktien Thema: Hauptdiskussion

Novavax press release (NASDAQ:NVAX): Q1 GAAP EPS of $2.93 beats by $2.22. Revenue of $666.66M (+609.2% Y/Y) beats by $322.81M. Total revenue for the first quarter of 2025 was $667 million, compared to $94 million in the same period in 2024. Higher product sales for the first quarter of 2025 were primarily due to $603 million of revenue recognized with the termination of two Advance Purchase Agreements (APA) and related to cash received in prior years. $45 million of Licensing, Royalties & Other Revenue in the first quarter of 2025 was higher than the prior year due to $40 million of Sanofi revenue associated with upfront payment and milestone amortization and cost reimbursement. Novavax is reiterating Full Year 2025 Financial Guidance for combined R&D and SG&A expenses and currently expects to achieve the following results:

https://seekingalpha.com/news/4444449-novavax-gaap-eps-of-2_93-beats-by-2_22-revenue-of-666_66m-beats-by-322_81m

Na Blechbüchse, alles fit? :)

15.30Uhr 🚀🚀🚀🚀🚀

sell sell

es fällt wieder 😚😚😚

Wie ich gesagt habe 10 Euro wird kommen

warte ab

Shorts are strong

😆😆😆😆😆

Das wird heute zweistellig

warte ab

Na dann schauen wir mal… wie sagt ein seltsames Wesen so gerne: Happy Happy Happy 🤣🤣

Erhöht den Umsatzrahmen für das Gesamtjahr 2025 auf zwischen 975 und 1.025 Millionen US-Dollar

😎

Endlich Klarheit bezüglich der Studie. Es geht lediglich um die PMC (NACH!) der Zulassung